You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Details for Patent: 8,420,592

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,420,592 protect, and when does it expire?

Patent 8,420,592 protects KIMYRSA and ORBACTIV and is included in two NDAs.

This patent has twenty patent family members in fifteen countries.

Summary for Patent: 8,420,592

Title:	Methods of treatment using single doses of oritavancin
Abstract:	Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Inventor(s):	Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)
Assignee:	The Medicines Company (Parsippany, NJ)
Application Number:	13/060,811
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,420,592

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Melinta Therap	KIMYRSA	oritavancin diphosphate	POWDER;INTRAVENOUS	214155-001	Mar 12, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT	⤷ Try a Trial
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,420,592

PCT Information
PCT Filed	August 29, 2009	PCT Application Number:	PCT/US2009/055466
PCT Publication Date:	March 04, 2010	PCT Publication Number:	WO2010/025438

International Family Members for US Patent 8,420,592

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009285564	⤷ Try a Trial
Canada	2736860	⤷ Try a Trial
China	102215858	⤷ Try a Trial
China	106620649	⤷ Try a Trial
Denmark	2337575	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.